NO309126B1 - Lyofilisert PGE-1-preparat - Google Patents
Lyofilisert PGE-1-preparat Download PDFInfo
- Publication number
- NO309126B1 NO309126B1 NO961718A NO961718A NO309126B1 NO 309126 B1 NO309126 B1 NO 309126B1 NO 961718 A NO961718 A NO 961718A NO 961718 A NO961718 A NO 961718A NO 309126 B1 NO309126 B1 NO 309126B1
- Authority
- NO
- Norway
- Prior art keywords
- pge
- preparation
- lactose
- stability
- butyl alcohol
- Prior art date
Links
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims description 49
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims abstract description 52
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 34
- 239000008101 lactose Substances 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000007710 freezing Methods 0.000 claims abstract description 11
- 238000001035 drying Methods 0.000 claims abstract description 10
- 230000008014 freezing Effects 0.000 claims abstract description 10
- 230000008569 process Effects 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000000872 buffer Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 6
- 239000007979 citrate buffer Substances 0.000 claims description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 6
- 239000001509 sodium citrate Substances 0.000 claims description 6
- 239000008351 acetate buffer Substances 0.000 claims description 3
- 238000000137 annealing Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract description 34
- 239000000243 solution Substances 0.000 abstract description 16
- 239000000203 mixture Substances 0.000 abstract description 11
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 abstract description 8
- 229960000711 alprostadil Drugs 0.000 abstract description 7
- 238000009472 formulation Methods 0.000 abstract description 7
- 150000003180 prostaglandins Chemical class 0.000 abstract description 3
- 238000010792 warming Methods 0.000 abstract description 2
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000012931 lyophilized formulation Substances 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 description 28
- 229960001375 lactose Drugs 0.000 description 28
- 239000000047 product Substances 0.000 description 27
- 230000015556 catabolic process Effects 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 229960004977 anhydrous lactose Drugs 0.000 description 5
- 239000006184 cosolvent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003708 ampul Substances 0.000 description 4
- 239000008228 bacteriostatic water for injection Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000008176 lyophilized powder Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- 238000001723 curing Methods 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940035429 isobutyl alcohol Drugs 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- KEAYESYHFKHZAL-IGMARMGPSA-N sodium-23 atom Chemical compound [23Na] KEAYESYHFKHZAL-IGMARMGPSA-N 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14369593A | 1993-10-27 | 1993-10-27 | |
| PCT/US1994/009648 WO1995011683A1 (en) | 1993-10-27 | 1994-09-06 | Stabilized prostaglandin e¿1? |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO961718L NO961718L (no) | 1996-04-29 |
| NO961718D0 NO961718D0 (no) | 1996-04-29 |
| NO309126B1 true NO309126B1 (no) | 2000-12-18 |
Family
ID=22505188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO961718A NO309126B1 (no) | 1993-10-27 | 1996-04-29 | Lyofilisert PGE-1-preparat |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US5741523A (de) |
| EP (1) | EP0725642B1 (de) |
| JP (1) | JP3999263B2 (de) |
| KR (1) | KR100335549B1 (de) |
| CN (1) | CN1060042C (de) |
| AT (1) | ATE187071T1 (de) |
| AU (1) | AU688792B2 (de) |
| DE (1) | DE69421936T2 (de) |
| DK (1) | DK0725642T3 (de) |
| ES (1) | ES2142409T3 (de) |
| FI (1) | FI116270B (de) |
| GR (1) | GR3032817T3 (de) |
| NO (1) | NO309126B1 (de) |
| NZ (1) | NZ273752A (de) |
| PT (1) | PT725642E (de) |
| WO (1) | WO1995011683A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| KR100195348B1 (ko) * | 1996-10-31 | 1999-06-15 | 장용택 | 안정한 프로스타글란딘 e1-함유 주사제 조성물 |
| US6103765A (en) | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
| AU742787B2 (en) | 1997-07-09 | 2002-01-10 | Androsolutions, Inc. | Improved methods and compositions for treating male erectile dysfunction |
| TR200002543T2 (tr) * | 1998-03-03 | 2000-11-21 | Shionogi & Co., Ltd. | Fosfolipaz önleyici sodyum [[3-(2-amino-1,2-dioksietil-1-fenilmetil) -2-etil-1-fenilmetil)- 1H-indol-4-il]oksi] asetat içeren farmasötik kompozisyonlar |
| US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US6264981B1 (en) † | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| JP4625637B2 (ja) | 2002-02-22 | 2011-02-02 | シャイア エルエルシー | 活性物質送達系及び活性物質を保護し投与する方法 |
| CA2543296A1 (en) * | 2003-10-31 | 2005-05-12 | Point Biomedical Corporation | Reconstitutable microsphere compositions useful as ultrasonic contrast agents |
| CN101933923A (zh) * | 2004-11-05 | 2011-01-05 | 赛福伦公司 | 癌症治疗 |
| US7464012B2 (en) * | 2004-12-10 | 2008-12-09 | L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude | Simplified process simulator |
| US7582312B2 (en) * | 2004-11-15 | 2009-09-01 | Discovery Laboratories, Inc. | Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| JPWO2006075690A1 (ja) * | 2005-01-14 | 2008-06-12 | 小野薬品工業株式会社 | 安定な医薬組成物 |
| US9005183B2 (en) * | 2007-05-16 | 2015-04-14 | Health Knight, Llc | System and method for treating erectile dysfunction |
| US20100222785A1 (en) * | 2007-08-03 | 2010-09-02 | Vanderbilt University | Anchor driver |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| EP2889029A1 (de) * | 2008-09-25 | 2015-07-01 | Cephalon, Inc. | Flüssige Formulierungen aus Bendamustin |
| SG172810A1 (en) * | 2009-01-15 | 2011-08-29 | Cephalon Inc | Novel forms of bendamustine free base |
| ES2875374T3 (es) | 2010-01-28 | 2021-11-10 | Eagle Pharmaceuticals Inc | Formulaciones de bendamustina |
| US10342769B2 (en) | 2014-11-14 | 2019-07-09 | Navinta Iii Inc | Carmustine pharmaceutical composition |
| AT518009A1 (de) * | 2015-07-27 | 2017-06-15 | Gebro Holding Gmbh | Konzentrat enthaltend Alprostadil |
| CN109394704B (zh) * | 2018-11-27 | 2021-09-17 | 西安力邦肇新生物科技有限公司 | 一种前列腺素e1甲酯注射用冻干制剂及制备和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3927197A (en) * | 1974-04-19 | 1975-12-16 | Pfizer | Tertiary alcohol stabilized E-series prostaglandins |
| US3952004A (en) * | 1974-06-18 | 1976-04-20 | Pfizer Inc. | Stabilized E-series prostaglandins |
| US4113882A (en) * | 1974-10-21 | 1978-09-12 | Yamanouchi Pharmaceutical Co., Ltd. | Stabilized oral prostaglandin formulation and the process for the preparation thereof |
| US5082664A (en) * | 1987-05-22 | 1992-01-21 | The Liposome Company, Inc. | Prostaglandin-lipid formulations |
-
1994
- 1994-09-06 WO PCT/US1994/009648 patent/WO1995011683A1/en active IP Right Grant
- 1994-09-06 AU AU77167/94A patent/AU688792B2/en not_active Ceased
- 1994-09-06 CN CN94193888A patent/CN1060042C/zh not_active Expired - Fee Related
- 1994-09-06 JP JP51260495A patent/JP3999263B2/ja not_active Expired - Lifetime
- 1994-09-06 US US08/619,690 patent/US5741523A/en not_active Expired - Lifetime
- 1994-09-06 ES ES94927958T patent/ES2142409T3/es not_active Expired - Lifetime
- 1994-09-06 AT AT94927958T patent/ATE187071T1/de not_active IP Right Cessation
- 1994-09-06 DK DK94927958T patent/DK0725642T3/da active
- 1994-09-06 KR KR1019960702158A patent/KR100335549B1/ko not_active IP Right Cessation
- 1994-09-06 PT PT94927958T patent/PT725642E/pt unknown
- 1994-09-06 DE DE69421936T patent/DE69421936T2/de not_active Expired - Lifetime
- 1994-09-06 NZ NZ273752A patent/NZ273752A/en not_active IP Right Cessation
- 1994-09-06 EP EP94927958A patent/EP0725642B1/de not_active Expired - Lifetime
-
1996
- 1996-04-26 FI FI961797A patent/FI116270B/fi active IP Right Grant
- 1996-04-29 NO NO961718A patent/NO309126B1/no not_active IP Right Cessation
- 1996-12-30 US US08/777,132 patent/US5770230A/en not_active Expired - Lifetime
-
2000
- 2000-02-29 GR GR20000400524T patent/GR3032817T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US5770230A (en) | 1998-06-23 |
| NO961718L (no) | 1996-04-29 |
| CN1133561A (zh) | 1996-10-16 |
| DE69421936D1 (de) | 2000-01-05 |
| JPH09504529A (ja) | 1997-05-06 |
| JP3999263B2 (ja) | 2007-10-31 |
| EP0725642B1 (de) | 1999-12-01 |
| US5741523A (en) | 1998-04-21 |
| GR3032817T3 (en) | 2000-06-30 |
| FI961797A0 (fi) | 1996-04-26 |
| DE69421936T2 (de) | 2000-06-29 |
| ES2142409T3 (es) | 2000-04-16 |
| NZ273752A (en) | 1998-03-25 |
| CN1060042C (zh) | 2001-01-03 |
| AU7716794A (en) | 1995-05-22 |
| PT725642E (pt) | 2000-05-31 |
| EP0725642A1 (de) | 1996-08-14 |
| DK0725642T3 (da) | 2000-05-29 |
| FI961797A (fi) | 1996-04-26 |
| KR960705572A (ko) | 1996-11-08 |
| NO961718D0 (no) | 1996-04-29 |
| AU688792B2 (en) | 1998-03-19 |
| FI116270B (fi) | 2005-10-31 |
| ATE187071T1 (de) | 1999-12-15 |
| KR100335549B1 (ko) | 2002-11-29 |
| WO1995011683A1 (en) | 1995-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO309126B1 (no) | Lyofilisert PGE-1-preparat | |
| NO309636B1 (no) | Fremgangsmåte for fremstilling av et krystallinsk amifostinpreparat samt doseringsformer av krystallinsk amifostin | |
| WO2001041800A9 (en) | Compositions and methods for stabilizing biological molecules upon lyophilization | |
| JPH11503719A (ja) | 乾燥組成物 | |
| EP1220685B1 (de) | Pharmazeutische zusammensetzung aus fibrinolytischem mittel | |
| EP3544584B1 (de) | Pharmazeutische parenterale formulierung mit carglumsäure | |
| IE67054B1 (en) | Growth hormone crystals and a process for production of these GH-crystals | |
| WO2012013742A2 (en) | Stabilization of fsh | |
| CA3125007A1 (en) | Collagenase formulations and methods of producing the same | |
| CZ287052B6 (en) | Lyophilized preparation containing 1,1,1-phosphinothioylidynetrisaziridine and process for preparing thereof | |
| EP0420964A1 (de) | Lyophilisierte peptid-formulierungen | |
| NO327142B1 (no) | Farmasoytisk preparat som omfatter en nukleotidanalog, mannitol og et modifiserende additiv, anvendelse av nevnte preparat samt fremgangsmate for dets fremstilling | |
| JPS62252722A (ja) | Ｎ−（２−ヒドロキシエチル）ニコチン酸アミド硝酸エステル含有注射剤 | |
| JP2003514032A (ja) | 安定な非晶質アミフォスチン組成物およびその製造法 | |
| JP4854899B2 (ja) | カルバペネム系抗生物質組成物の処方方法 | |
| KR20180040158A (ko) | 알긴산 동결 건조 제제 | |
| EP4070785B1 (de) | Lyophilisierte zusammensetzung von einem copanlisib-salz | |
| EP3817760B1 (de) | Lyophilisierungsverfahren und dadurch hergestelltes teverelix-tfa-lyophilisat | |
| WO2021009595A1 (en) | Cyclophosphamide injectable composition and methods for producing same | |
| CN116421569A (zh) | 一种注射用帕瑞昔布钠药物组合物及其制备方法 | |
| EP0437621A1 (de) | Wässrige lösung von motilin | |
| EP1913956A1 (de) | Zusammensetzungen und Verfahren zur Stabilisierung biologischer Moleküle bei der Gefriertrocknung | |
| WO2022169582A1 (en) | Compositions and methods for clear concentrated parenteral delivery of dantrolene therapeutic agents | |
| CN115998690A (zh) | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 | |
| CN114929202A (zh) | 含有2-[(3-氨丙基)氨基]乙硫醇的冻干粉末及其用于制备热凝胶的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |